BIOGAIA Aktie

 

The number of votes in BioGaia decreased during May as a result of the conversion of a total of 1,038,202 Class A shares into 1,038,202 Class B shares. The conversion was carried out based on the provision in the Articles of Association, introduced at the Annual General Meeting on May 7, 2025, allowing Class A shareholders to request conversion of Class A shares into Class B shares. As of May 30, 2025, the total number of shares in BioGaia amounts to 101,162,310 of which 2,665,138 are Class A shares with ten votes each and 98,497,172 are Class B shares with one vote each, totaling 125,...

BioGaia has been recognized by TIME Magazine´s and Statista's prestigious list of the World's Top 500 Companies Pairing Growth with Environmental Stewardship. This recognition highlights BioGaia's commitment to combining strong business performance with responsible environmental practices. The ranking evaluates 5,000 global companies based on three core dimensions: revenue growth, financial stability, and environmental impact. The environmental assessment focuses on carbon emissions across Scope 1, 2, and 3, both in total and relative to revenue and industry peers. Other factors such as...

The Annual General Meeting of BioGaia AB (publ) on 7 May 2025 voted, among other things, to approve the following resolutions: - adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet - discharge from liability for the Board members and the CEO - a dividend of SEK 1.95 per share plus an extra dividend of SEK 4.95 per share resulting in a total dividend of SEK 6.90 per share and a grant of SEK 5.0 million to “The Foundation to Prevent Antibiotic Resistance” that was founded by BioGaia in 2017. The purpose of the...

BioGaia AB (NASDAQ: BIOG) is expanding its global footprint by establishing direct sales in the Netherlands initially through an online approach. BioGaia will launch sales of its products on the major local marketplaces, Bol.com and Amazon.nl. This initiative supports BioGaia's long-term strategy to expand through direct sales and bring its clinically proven probiotics closer to consumers. The Netherlands is one of the last countries in Europe where our products are not yet available through our own direct sales or a distributor. Given the strong potential and increasing interest in...

FIRST QUARTER 2025 Net sales amounted to SEK 366.3 million (369.8), a decrease of SEK 3.5 million, or a decrease of 1% (excluding foreign exchange effects a decrease of 3.6%). Net sales in the Pediatrics segment amounted to SEK 269.9 million (292.3), a decrease of 8% (excluding foreign exchange effects a decrease of 10%). Net sales in the Adult Health segment amounted to SEK 94.6 million (74.8), an increase of 26% (excluding foreign exchange effects an increase of 23%). Operating expenses amounted to SEK 171.2 million (122.6), an increase of SEK 48.6 million (40%). Operating...

BioGaia's (NASDAQ: BIOG) financial report for the first quarter of 2025 will be published at approximately 8:00 AM CEST on May 7, 2025. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a...

BioGaia AB (publ) will hold its Annual General Meeting at 4 p.m. on 7 May 2025, at Klara Konferens & Happynings på Klara Strand, Klarabergsviadukten 90, in Stockholm. The doors will be opened for registration at 3:30 p.m. Right to participate In order to participate in the Annual General Meeting (AGM), shareholders must be recorded in the register of shareholders maintained by Euroclear Sweden AB relating to the circumstances on 28 April 2025 and must provide notice of participation to the company no later than 30 April 2025. Notification can be made by mail to BioGaia AB (publ), P.O....

BioGaia´s (NASDAQ: BIOG) Annual and Sustainability Report 2024, including Corporate Governance Report 2024, and the Remuneration Report 2024 in Swedish as well as an English translation are now available to download from the BioGaia website: https://www.biogaiagroup.com/investors/reports-and-presentations/annual-reports The Swedish Annual and Sustainability Report 2024 is also available on BioGaia's website in European Single Electronic Format (ESEF). Follow us: Subscribe to BioGaia press releases here (https://www.biogaiagroup.com/newsroom/subscribe-to-press-releases) LinkedIn here...

BioGaia AB (NASDAQ: BIOG) announces that Annwall & Rothschild Investments AB (owned by Jan Annwall and BioGaia's Chairman Peter Rothschild), another member of the Rothschild family and David Dangoor (BioGaia's Vice Chairman), have entered into an agreement whereby Annwall & Rothschild Investments AB will sell all of its BioGaia shares, and David Dangoor and the other Rothschild family member will sell half of their shares in BioGaia, to existing BioGaia shareholders Anatom Holding AG (“Anatom”) and other separate entities, all owned by different members of the Kahane family. “I believe this...

BioGaia's (NASDAQ: BIOG) financial report for the fourth quarter of 2024 will be published at approximately 8:00 AM CET on February 12, 2025. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CET. To join the audiocast with teleconference and ask a...

In line with its long-term strategy to market and sell its product through own subsidiaries in certain prioritized markets, BioGaia AB has terminated the contract with its current partner in France in accordance with terms of the contract. The company is preparing to launch the business directly through its own subsidiary in France later this year. Currently, nearly half of the population in France has consumed probiotics within the past 24 months. A growing health consciousness among French consumers has led to increased recognition of the benefits of high-quality, scientifically...

We are proud to launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and...

BioGaia AB (NASDAQ: BIOG) announces that Anatom Holding AG, a Switzerland-based investment firm, has acquired 4,979,813 class B shares in BioGaia AB following the exit of EQT Public Value fund. This acquisition represents 4.9% of BioGaia's total shares and 3.7% of the total voting rights. The transaction, which is not subject to any conditions, was completed on October 31, 2024. BioGaia, a global leader in probiotics, welcomes Anatom Holding as a long-term investor. Anatom Holding, an independent investment firm managed by the Kahane Family, specializes in providing strategic capital to...

THIRD QUARTER 2024 (For balance sheet items, figures in parentheses refer to year-end 2023 figures. For income statement and cash flow items, they refer to the same period last year). Net sales amounted to SEK 304.0 million (317.7), a decrease of SEK 13.7 million, or 4% (excluding foreign exchange effects a decrease of 2%). Net sales in the Pediatrics segment amounted to SEK 225.8 million (255.8), a decrease of 12% (excluding foreign exchange effects a decrease of 9%). Net sales in the Adult Health segment amounted to SEK 76.6 million (59.2), an increase of 29% (excluding foreign...

(Figures in the brackets refer to the same period the previous year) During the third quarter of 2024, BioGaia will record a non-cash impairment of SEK 51.2 million, relating to the acquisition of MetaboGen AB. The impairment loss is mainly caused by a clinical study that did not meet its primary endpoints which resulted in updated assumptions of the impairment model. The study aimed to prove the efficacy of a next-generation probiotic product for individuals with metabolic syndrome. For the third quarter, sales are preliminarily estimated at SEK 304 million (318), a decrease of 4%....

BioGaia AB's Nomination Committee for the Annual General Meeting 2025 has been appointed based on the ownership structure as of June 30, 2024. The Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Jacob Sellman, EQT, Jannis Kitsakis, appointed by AP4, and Thomas Brown, Premier Miton Investors. In addition, Peter Rothschild is a member of the...

BioGaia's (NASDAQ: BIOG) financial report for the third quarter of 2024 will be published at approximately 8:00 AM CEST on October 22, 2024. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a...

The number of shares and votes in BioGaia AB (publ) increased in September due to the exercise of some warrants issued under the BioGaia incentive program 2021/2024 for subscription of shares. Through this subscription, the number of Class B shares and votes in BioGaia increased by 5,000 and the share capital increased by SEK 1,000. As of September 30, 2024, the total number of shares in BioGaia amounts to 101,162,310 of which 3,703,340 are Class A shares with ten votes each and 97,458,970 are Class B shares with one vote each, totaling 134,492,370 votes. Additionally, the share capital...

The number of shares and votes in BioGaia AB (publ) increased in August due to the exercise of some warrants issued under the BioGaia incentive program 2021/2024 for subscription of shares. Through this subscription, the number of Class B shares and votes in BioGaia increased by 140,000 and the share capital increased by SEK 28,000. As of August 30, 2024, the total number of shares in BioGaia amounts to 101,157,310 of which 3,703,340 are Class A shares with ten votes each and 97,453,970 are Class B shares with one vote each, totaling 134,487,370 votes. Additionally, the share capital...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE OR OFFERS OR SALES WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AND IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN...